

## **Organon and Tiko advance access to sexual health services and education across South Africa**

*Educating, supporting and empowering young ladies in our communities with services and information on menstruation and sexual reproductive health.*

JOHANNESBURG – Today a Memorandum of Understanding (MoU) was signed between Organon, a global healthcare company focused on women's health and Tiko Africa, a non-profit organisation which focuses on aiding young girls to gain access to sexual health services and information through a digital platform.

The timing of this signing on the 10-year Remembrance of President Mandela's passing is significant to his vision of making a positive impact in our own communities. In line with this year's call to action that "The Legacy Lives on Through You", the goal with this MoU is to reach 67 000 young girls across South Africa and empower them when it comes to their reproductive health.

The MoU was signed by Organon CEO, Mr. Kevin Ali and Ms. Hameline Chimuka from Tiko Africa. The purpose of the memorandum is to ensure that young girls across the continent have increased access to youth friendly sexual health and wellbeing services, receive the correct menstrual information and education from reputable providers and trained individuals in safe places within their communities. The accomplishment of getting this project off the ground aligns directly with Organon's goal of preventing an estimated 120 million unplanned pregnancies by 2030 through their Her Promise Access Initiative Programme. Furthermore, Tiko Africa has had great success reaching young girls and giving them access to youth friendly services and information on various contraception offerings and on how to get assistance with access to contraception safely and conveniently through their digital platform.

Kevin Ali, Organon CEO noted, "This strategic partnership with Tiko is particularly important, especially in sub-Saharan Africa where young girls are not only faced with misinformation and menstruation poverty, but also face days away from school every month along with other social factors. Through this programme, we will be able to educate, equip and empower these young women with their health needs from menstruation to affordable, accessible sexual reproductive health options. We are positive that this will not only help to reduce the number of unplanned pregnancies but also create opportunities for communities to support their youth through open dialogue on this topic. I look forward to what we can achieve as we continue to be here for her health."

Benoit Renard, Tiko Africa founder and CEO noted: "Our innovative digital platform, Tiko, works at building a two-sided market where information provided to young girls through on the ground mobilisation, educational workshops championed by partner organisations leads to greater access to essential services in their communities, where their voice is heard and their choice respected. Through this strategic partnership with Organon, we believe that we can build a thriving ecosystem of partners working together to ensure girls reach their potential and fulfil their dreams."

The MoU constitutes a framework to support the cooperation between Organon and Tiko to pilot this programme in communities where access to essential services and information is most needed. Interactive workshops, availability of school nurses at clinics and access to affordable services and products are going to be the initial steps

these businesses will take in consultation with the relevant government departments in order to provide the necessary services.

“Organon SSA is dedicated to implementing positive changes in the lives of young African girls. The implications of sexual health misinformation and lack of appropriate wellbeing services has far reaching consequences not only on the health of these young ladies but also on their future. Our purpose is to empower young ladies to reach their full potential and become active and productive members of society as we move Africa forward,” added Organon SSA MD, Abofele Khoele.

### **About Organon**

Organon is a global healthcare company formed to focus on improving the health of women throughout their lives. We build upon our strong foundation of more than 60 medicines and solutions across a range of areas including reproductive health, heart disease, allergies and asthma.

Organon’s existing products produce strong cash flows that support investments in innovation and future growth opportunities in women’s health and biosimilars. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast growing international markets.

Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 10,000 employees with headquarters located in Jersey City, New Jersey.

Media Contact:

Luyanda Msiya

Corporate Communications Lead

Email: [Luyanda.Msiya@organon.com](mailto:Luyanda.Msiya@organon.com))

Phone number: +27 871069655

For more information, visit <https://www.organon.com/south-africa> and connect with us on [LinkedIn](#), Instagram, [Twitter](#) and [Facebook](#).

### **Cautionary Note Regarding Forward-Looking Statements**

Some statements and disclosures in this news release are “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts and can be identified by the use of words such as “goals”, “may,” “expects,” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” “will,” or words of similar meaning. These forward-looking statements are based on our current plans and expectations and are subject to a number of risks and uncertainties that could cause our plans and expectations, including actual results, to differ materially from the forward-looking statements. Organon undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.